OUR PLATFORMS
Rooted in decades of experience in molecular biology, deep understandings of molecular diagnostics, and a wide range of OMICs technologies, Complete Omics has been working with world’s leaders in cancer proteomics and cancer genomics. Throughout the past decade, Complete Omics has established several robust platforms meeting the most demanding yet critical needs from basic research and clinical applications. We are well equipped to help you with your projects through our following patented or proprietary platforms:
Genomics
Patented DEEPER-Seq Platform — the world’s only barcoded single-strand library PLUS dual-RNA probe capture approach
Proteomics
Patented MT-SRM, SAFE-SRM, MANA-SRM, Neo-True Platforms — world’s leading authority in quantitative proteomics
Metabolomics
Proprietary MetaBoost chemical derivatizations for extremely sensitive detection and quantification of small molecules.
Please click on each specific technology above to learn more about Complete Omics’ expertise and our vision in clinical applications…
PIONEERING IN MULTI-OMICS CANCER DIAGNOSTICS SINCE 2010
In 2010, Dr. Qing Wang reported the 1st pipeline for detecting mutant proteins as cancer-specific biomarkers through Mass Spectrometry following NGS (next-generation sequencing)-based identification of personalized mutations, and the work was published on PNAS on Jan 19 2011. Through the past 10 years, we have been pioneering the developments of clinical multi-omics technologies including the 1st clinical proteomics-based ovarian cancer diagnostic platform, the 1st personalized cancer neoantigen therapeutic target detection and quantification platform, the most in-depth plasma proteomics pipeline (quantifying 4,550 proteins in plasma), the world’s only dual-RNA probe-based targeted NGS pipeline, etc. We are currently looking for active collaborations with clinical service providers to utilize our numerous platforms for your molecular diagnostics projects. We are interested in all kinds of collaboration and business opportunities!
Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.
Complete Omics published novel technologies on SCIENCE and SCIENCE IMMUNOLOGY.
To identify truly personalized cancer therapeutic target is the 1st step of the personalized cancer therapeutics. Complete Omics’ Multi-Omics molecular diagnostic pipeline has achieved two extraordinary achievements in this new incoming era, and we are dedicated to develop more advanced multi-omics molecular diagnostic technologies and will focus on taking them to rapid commercialization.
Congratulations to our lab alumni founders in Thrive Earlier Detection.
NEW YORK – Exact Sciences has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection for cash and stock consideration of up to $2.15 billion.
“We see each individual as an integrity of multiple universes. We are striving to provide the most sensitive and specific health surveillance tests through measuring the individual’s different pools of biological molecules simutaneously.”
— Qing Wang, Founder and CEO
Our People | check here for the team of Complete Omics |
Complete Omics is incorporated by a vibrant team of excellent scientists. With decades of expertises in molecular diagnostics and Omics-based technologies, our scientists and directors are building something fantastic for human population. We are hiking alone, but are determined to change the world!
2021–Direct Quantification of Neoantigens Like Never Before — published on Science and Science Immunology
Genetic changes in human genome are the driving force for all cancers. Different patients have different sets of mutation profiles even when the patients all have the same disease. For decades, doctors, cancer scientists, and pharmaceutical companies have been working tirelessly trying to find a way to treat each person’s unique disease in a highly personalized way that will reach the maximum treatment efficacy with the lowest side effects. Complete Omics, working with leaders in cancer therapeutics, has developed two applications based on our Valid-NEO pipeline through which we clearly saw personalized therapeutic targets on the cancer cell surface before adopting a highly specific treatment, for here bispecific antibodies. Two papers describing our new technologies are puslished on Science (Ref. 1) and Science Immunology (Ref. 2). Our pipeline has been reported by GenomeWeb (Ref. 3)
Prediction-FREE Neoantigen Validation Enables Personalized Cancer Therapeutics
Latest News
Collaboration with Yale University
Sept 16, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Dianqing (Dan) Wu from Yale University on a series of quantitative proteomics focusing on leveraging…
Collaboration with Taipei Medical University
Aug 30, 2021 | BALTIMORE – Complete Omics’ Clinical Genomics team announced a collaboration with Professor Ching-shuen Wang from Taipei Medical University on a series of RNA-seq projects leveraging our…
Collaboration with Duke University
July 18, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Dr. Yiping He from Duke University on a series of grants focusing on leveraging our…
